Novel and innovative product and production processes for pharmaceuticalsVan Derden
As novel products and processes are rapidly expanding in the pharma industry, we would like to share with you various new developments in the fields of Advanced Therapy Medicinal Products and insights from technology providers. With topics such as personalized medicine, modular production technology and increasing levels of automation and integration for biosimilar production, we hope to be able to inform you about exciting new trends within the pharmaceutical industry in the Netherlands.
This event will be organized at Kiadis Pharma, based in Amsterdam South-East.
For the Young Professionals, there will be a parallel program where PME-Progress and Yxion will discuss topics that are relevant for the new generation of professionals.
The regular program will close with drinks followed by a dinner (for those interested, at additional costs).
More information & Registration
Click here for more information
13:00 Doors open
Introduction to ISPE – by René van Opstal – Chair ISPE Netherlands
Introduction to Kiadis, cell therapy supply chain, and recent evolutions in the company – by Dirk de Naeyer
13:45 Presentation Kiadis pharma
Cell therapy process development and commercialization – setting standards for an emerging field – by Mathieu Streefland
14:45 Presentation GE healthcare life sciences
Addressing complexities in modular cell therapy manufacturing workflows – by Gonçalo Regalo
14:45 Young Professionals presentation Yxion
15:45 presentation miltenyi biotech
The future of GMP cell manufacturing – by Martha Elia Luevano Salinas
15:45 Young Professionals presentation progress PME
Feasibility of a biosimilar plant
16:30 Presentation Biosana
An interactive Q&A session on the development of new technology for pharma and the challenges encountered – by Ard Tijsterman
17:15 End of program
17:30 Drinks and Young Professionals event
During the drinks, various companies will “pitch” themselves to the young professionals present as a way of introducing themselves to the next generation of pharma professionals
Requires separate indication at registration – at additional costs